Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
What Biofrontera’s Phase 3 results mean for non-facial actinic keratosis treatment strategies
Biofrontera reports positive Phase 3 Ameluz data outside the face and scalp. Find out how this could change actinic keratosis treatment.
Why Biofrontera Inc.’s dual database locks mark a critical step toward validated clinical and regulatory data
Biofrontera Inc. has confirmed that databases for two of its clinical studies have been formally locked, a procedural milestone that signals the completion of data collection and validation and the transition into final statistical analysis. Although database locks rarely attract the same level of attention as topline efficacy readouts, they represent one of the most […]